Aesica appoints new site manufacturing manager at Cramlington facility
Tasked with optimising performance schedules, including 4 new products for 2014
25 November 2013 – USA: Aesica, the global contract development and manufacturing organisation (CDMO), has today announced the appointment of Catherine Dick to the new role of site manufacturing manager at Cramlington. She will take responsibility for ensuring that all manufacturing is performed as planned from product introduction through all aspects of the manufacturing process.
A key function for Catherine is to ensure that every activity scheduled is kept on track for products during the remainder of 2013. This includes the completion of manufacturing work on approximately 4 new products, at multiple stages of development, due to be brought on to the Cramlington site in 2014, each of which will be manufactured for a key strategic partner of Aesica.
Catherine brings strong experience and knowledge of operations at Cramlington to the task in hand, having joined Aesica back in 2007 as the site’s Quality Manager. In 2010, she was promoted to Head of Quality for UK API (Active Pharmaceutical Ingredients), responsible for the quality and regulatory compliance of all products manufactured across both the Cramlington and the Queenborough API manufacturing sites. Recently, she headed up the latest Queenborough API MHRA site inspection, carried out voluntarily by the company every three years.
Mark Dawson will now take the helm as Head of Quality at the Cramlington facility. With over 25 years’ experience in the API industry, Mark has held various roles at the site within the Quality Control, EH&S and Warehousing departments. In his most recent role, he spent thirteen years as part of the production management team responsible for the day-to-day running of the process plants on the Cramlington site.
The company is also set to recruit three new chemists, a site engineering manager and an analytical technology officer.
Catherine had previously worked as QA Manager and as a project manager for a small biotechnology company prior to joining Aesica. She holds an MSC research fellowship in mechanisms of iron uptake in plants, microbes and mammalian cells, a PhD in BioChemistry from Newcastle University and a degree in BioChemistry and Genetics from Durham.
Steve Barker, Operations Director, API Business Unit at Aesica remarked: “Catherine possesses strong expertise and a solid knowledge of implementing work on multiple, quality APIs. The acumen she brings to the role coupled with the collective quality measures we are taking will ensure the company operates to the most rigorous, cost effective and timely manufacturing processes.”
Aesica supplies contract development and contract manufacturing services for Formulated Products and Active Pharmaceutical Ingredients to a host of the world’s leading pharmaceutical companies and emerging biotechnology organisations.
The uniqueness of Aesica lies in its flexible and bespoke approach to service delivery, coupled with its ability to develop products from the initial clinical stage through to final commercial supply. It is this all-encompassing offering combined with its dedication to exceptional standards of service that truly sets Aesica apart from its counterparts.
Aesica is one of the UK’s fastest growing companies and over the last five years has more than trebled its turnover.
- The company currently employs approximately 1,300 people.
- In addition to its headquarters in Newcastle upon Tyne, UK, Aesica has development and manufacturing sites across Europe including Cramlington, Nottingham and Queenborough in the UK, as well as sites in Monheim and Zwickau in Germany and Pianezza in Italy. It also has sales representation in San Diego and Shanghai.
- The vision of Aesica is to become the number one supplier of APIs and formulated products to the pharmaceutical industry.